Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th

- Virtual event to take place from 8:00 a.m. to 9:30 a.m. EDT -

HAMILTON, Bermuda, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways that are implicated across a spectrum of diseases, today announced that the company’s virtual Rilonacept Analyst Day will now take place on Tuesday, September 29^th, 2020 from 8:00 a.m. to 9:30 a.m. Eastern Daylight Time.

The event will feature presentations from the Kiniksa management team on the market opportunity for rilonacept in recurrent pericarditis as well as the company’s continued commercial preparations and launch strategy. Additionally, guest speaker Paul Cremer, MD, Cardiovascular Medicine, Cleveland Clinic, will review the burden of recurrent pericarditis, the current treatment landscape, and the unmet need.

Webcast and Conference Call Information
Kiniksa will host a webcast and conference call at 8:00 a.m. Eastern Daylight Time on Tuesday, September 29^th, 2020. The presentation will be accessible through this link as well as through the Investors & Media section of the company's website. Individuals can also participate by dialing [phone] (U.S. and Canada) or [phone] (international) using conference ID number 3890078. The archived webcast will be available on Kiniksa’s website for 14 days beginning approximately one hour after the conclusion of the event.

About Recurrent Pericarditis
Recurrent pericarditis is a painful and debilitating autoinflammatory cardiovascular disease that typically presents with chest pain and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Patients with pericarditis are deemed recurrent if they have an additional episode after a symptom-free period of 4-6 weeks, and chronic if symptoms from any one episode last longer than three months. Recurrent pericarditis symptoms impair qualify of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. There are currently no U.S. Food and Drug Administration (FDA)-approved treatments for recurrent pericarditis.